Glanbia PLC Reports Strong Q3 2025 Performance and Upscales Full‑Year Guidance
Earnings and Revenue Highlights
Glanbia PLC released its interim management statement for the nine months ended 4 October 2025, reporting that like‑for‑like revenue rose 3.3 %. The increase was driven mainly by volume growth across all segments, with the Performance Nutrition division posting a 14.3 % rise in sales of the Optimum Nutrition brand. The company’s Performance Nutrition segment also noted an acceleration in the third quarter compared with the prior period.
Guidance Revision
In response to the robust results, Glanbia upgraded its full‑year revenue guidance. The nutrition group now anticipates higher total revenue for 2025, citing sustained momentum in the third quarter and strong demand for its product portfolio. The updated guidance was announced in an interim management statement and subsequently confirmed during the earnings call held on 5 November 2025.
Market Reaction
Following the announcement, Glanbia’s shares rose in the Irish Stock Exchange All Market. Market participants noted the company’s positive outlook for the remainder of the year, and the stock’s price increased from its previous close of 14.4 EUR to 15.05 EUR on 23 October 2025, its 52‑week high.
Segment Performance
- Glanbia Performance Nutrition – sales up 14.3 % in Q3, driven by the Optimum Nutrition brand.
- Glanbia Nutritionals – benefited from volume increases, contributing to the overall 3.3 % revenue growth.
- Glanbia Ireland – supported the group’s revenue expansion, though specific figures were not disclosed.
Industry Context
The nutrition and dietary supplements market continues to expand globally, with recent market research indicating growth in pea protein and softgel supplement segments. These trends support Glanbia’s strategic focus on plant‑based proteins and preventive health products.
Financial Snapshot
| Metric | Value |
|---|---|
| Market Capitalisation | 3.53 billion EUR |
| Price‑to‑Earnings (P/E) | 14.38 |
| 52‑Week High | 15.05 EUR |
| 52‑Week Low | 9.20 EUR |
| Current Close (3 Nov 2025) | 14.40 EUR |
The company’s upgraded guidance reflects confidence in continued demand for its nutrition solutions, positioning Glanbia for a solid performance throughout 2025.
